US/UK/Canada

Share

Pick a time period -
Tags ( Active)

InDex Pharmaceuticals to host virtual R&D day on December 8, 2020

November 26, 2020 – InDex Pharmaceuticals Holding AB (publ) (”InDex”) today announced that the company will host a virtual R&D day on Tuesday December 8, 2020 for investors, analysts and media.The purpose of the R&D day is to provide an overview of ulcerative colitis and the drug candidate cobitolimod from a scientific and market perspective. Cobitolimod is a first-in-class Toll-like receptor 9 (TLR9) agonist under development by InDex as a novel therapy for moderate to severe ulcerative colitis. After meeting the primary endpoint in the phase IIb study CONDUCT with an outstanding

The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals’ results of the phase IIb study with cobitolimod

October 6, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study have been published in the high-impact medical journal The Lancet Gastroenterology and Hepatology. CONDUCT was a phase IIb dose optimisation study, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. The study met the primary endpoint and cobitolimod demonstrated an outstanding combination of efficacy and safety.“We are delighted that the CONDUCT study results have been published in a prestigious journal, which is one

InDex Pharmaceuticals to present the successful results of the CONDUCT study at two leading medical conferences

August 24, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study will be presented orally at two leading gastroenterology conferences; the United European Gastroenterology Week (UEGW) and the American College of Gastroenterology (ACG) Annual Scientific Meeting. CONDUCT was a phase IIb dose optimisation study, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. The study met the primary endpoint with an outstanding combination of efficacy and safety.“We are very pleased that the

InDex Pharmaceuticals presents at Redeye Growth Day 2020

May 26, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day 2020 on June 2 at 15.50 CET. The presentation will be livestreamed and can be followed at https://www.redeye.se/live/growth-day-2020.The presentation will also be available afterwards on https://www.redeye.se/live/growth-day-2020, on  the company’s page in Redeye Universe (www.redeye.se/company/index-pharmaceuticals), as well as on InDex’s website (www.indexpharma.com).   For more information: Peter Zerhouni, CEOPhone: +46 8 508 847 35E-

InDex Pharmaceuticals Holding AB (publ) interim report January – March 2020

FDA and EMA endorse the advancement of cobitolimod into phase III studies“The positive responses from the regulators is an important external validation of our study results and cobitolimod’s potential,” says Peter Zerhouni, CEO of InDex Pharmaceuticals. Period January – March 2020 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –24.0 (–17.2) million · Result after tax amounted to SEK –24.0 (–17.2) million, corresponding to SEK –0.27 per share (–0.25) before and after dilution · Cash flow from operating activities amounted to SEK –21.9 (–18.4)

InDex Pharmaceuticals advances cobitolimod further towards phase III following successful interactions with FDA and EMA

April 16, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has received positive responses from FDA and EMA regarding phase III development of the company's TLR9 agonist cobitolimod, for the treatment of moderate to severe ulcerative colitis. The company is continuing its phase III preparations, including efforts to secure financing.Following the phase IIb study CONDUCT meeting its primary endpoint in August 2019, dialogues were initiated with FDA and EMA respectively, for the further development of cobitolimod. These processes have now been completed and both

InDex Pharmaceuticals Holding AB (publ) year-end report 2019

Cobitolimod’s outstanding combination of efficacy and safety confirmed in in-depth analysis“The robustness and consistency of the CONDUCT results support our strategy to move cobitolimod forward in development and our phase III preparations are continuing according to plan,” says Peter Zerhouni, CEO of InDex Pharmaceuticals.    Period October – December 2019 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –25.6 (–22.3) million · Result after tax amounted to SEK –25.6 (–22.3) million, corresponding to SEK –0.29 per share (–0.33) before and

InDex Pharmaceuticals’ in-depth analysis of the CONDUCT study confirms the successful top line results and supports the strategy going forward

February 19, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced the conclusions from in-depth analysis of the complete data set from the phase IIb dose optimisation study CONDUCT, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. The analysis confirms that the highest dose tested, which met the primary endpoint of the study, demonstrates an outstanding combination of efficacy and safety.In-depth analysis of the complete data set has now been concluded and hence the Clinical Study Report can be finalised. As

InDex Pharmaceuticals Holding AB (publ) interim report January – September 2019

Outstanding combination of efficacy and safety in the CONDUCT study“Something that really differentiates cobitolimod from its competitors is the superior safety profile. Both the approved drugs and those currently being tested in phase III are associated with serious side effects. With an outstanding combination of efficacy and safety, cobitolimod is set to take a leading position within the field,” said Peter Zerhouni, CEO of InDex Pharmaceuticals. Period July – September 2019 · Revenues amounted to SEK 0.0 (0.0) million · Operating result amounted to SEK –27.2 (–15.1) million

InDex Pharmaceuticals meets primary endpoint in the phase IIb study CONDUCT with cobitolimod in ulcerative colitis

· Outstanding combination of efficacy and safety · 15% delta vs. placebo for clinical remission August 27, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced positive top line results from the dose optimisation study CONDUCT, which is evaluating cobitolimod for the treatment of moderate to severe ulcerative colitis. The study met the primary endpoint of clinical remission, demonstrating a superior efficacy of 15% (delta) in patients receiving the highest dose of cobitolimod compared to placebo. Cobitolimod was well tolerated at all dose levels and no differences in the

InDex Pharmaceuticals Holding AB (publ) interim report January – June 2019

Last patient enrolled in the CONDUCT studyPeriod April – June 2019   ·  Revenues amounted to SEK 0.0 (0.0) million ·  Operating result amounted to SEK –17.7 (–26.0) million ·  Result after tax amounted to SEK –17.7 (–26.0) million, corresponding to SEK –0.26 per share (–0.42) before and after dilution ·  Cash flow from operating activities amounted to SEK –13.9 (–19.7) million Period January – June 2019 ·  Revenues amounted to SEK 0.0 (0.1) million ·  Operating result amounted to SEK –34.9 (–44.7) million ·  Result after tax amounted to SEK –34.9 (–44.7) million,

InDex Pharmaceuticals enrolls last patient in phase IIb study CONDUCT with cobitolimod

June 26, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that patient enrolment was completed in the dose optimisation study CONDUCT, which is evaluating cobitolimod for the treatment of moderate to severe ulcerative colitis. Top line results are expected to be available in 8-10 weeks.The CONDUCT study is a randomised, double blind, placebo-controlled phase IIb study designed to evaluate the TLR9 agonist cobitolimod’s efficacy and safety in inducing clinical remission, compared to placebo, in patients with left-sided moderate to severe active ulcerative colitis who have not

InDex Pharmaceuticals presents at Redeye Growth Day on June 10, 2019

June 3, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day at Haymarket by Scandic, Hötorget 13-15, in Stockholm on June 10 at 14.40 CET. The presentation will be livestreamed and can be followed at www.redeye.se/live/redeye-growth-day-19.The presentation will also be available afterwards at www.redeye.se/live/redeye-growth-day-19, on the company’s page in Redeye Universe (www.redeye.se/company/index-pharmaceuticals), as well as on the company’s website (www.indexpharma.com). For more information:Peter

InDex Pharmaceuticals presents at the Introduce Investor Days

May 23, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at the Introduce Investor Days at Haymarket by Scandic in Stockholm on May 27 at 9.30 CET.The event is hosted by ABG Sundal Collier and is open for both private and institutional investors. The presentation will also be livestreamed and can be followed at www.introduce.se. For more information:Peter Zerhouni, CEOPhone: +46 8 508 847 35E-mail: peter.zerhouni@indexpharma.com  InDex Pharmaceuticals in briefInDex is a pharmaceutical development company focusing

Bulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)

May 6, 2019 – The Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) took place on Monday, May 6, 2019 in the company´s premises at Tomtebodavägen 23a in Stockholm, Sweden.The complete bulletin from the Annual General Meeting (in the Swedish language) is available on the company’s website, www.indexpharma.com. For more information:Peter Zerhouni, CEOPhone: +46 8 508 847 35E-mail: peter.zerhouni@indexpharma.com  PublicationThe information was submitted for publication through the agency of the contact person set out above at 19:00 CET on May 6, 2019. InDex

InDex Pharmaceuticals Holding AB (publ) interim report January – March 2019

The final phase of the patient recruitment in the CONDUCT studyPeriod January – March 2019   ·  Revenues amounted to SEK 0.0 (0.1) million ·  Operating result amounted to SEK –17.2 (–18.8) million ·  Result after tax amounted to SEK –17.2 (–18.7) million, corresponding to SEK –0.25 per share (–0.30) before and after dilution ·  Cash flow from operating activities amounted to SEK –18.6 (–22.9) million ·  Cash and cash equivalents at the end of the period amounted to SEK 64.4 (102.1) million ·  Number of employees at the end of the period was 7 (7) ·  Number of shares

InDex Pharmaceuticals provides status update on the patient recruitment in the CONDUCT study

April 11, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that 197 patients, of the total 215 planned, have been enrolled to date in the CONDUCT study evaluating the drug candidate cobitolimod. The patient recruitment has varied significantly on a monthly basis, with between 6 and 19 patients enrolled, which makes it challenging to predict the remaining recruitment time. The company estimates that the patient recruitment will be completed during the month of June at the latest, which represents a delay compared to the previously communicated timeline. The company will announce

InDex Pharmaceuticals Holding AB (publ) year end report 2018

Continued focus on the patient recruitment for the CONDUCT studyPeriod October – December 2018 ·  Revenues amounted to SEK 0.6 (0.0) million ·  Operating result amounted to SEK –22.5 (–22.6) million ·  Result after tax amounted to SEK –22.5 (–22.4) million, corresponding to SEK –0.33 per share (–0.36) before and after dilution ·  Cash flow from operating activities amounted to SEK –20.9 (–14.1) million  Period January – December 2018  ·  Revenues amounted to SEK 0.7 (0.1) million ·  Operating result amounted to SEK –82.4 (–73.3) million ·  Result after tax

InDex Pharmaceuticals carries out a directed share issue of approximately SEK 37.5 million

October 23, 2018 – The board of directors of InDex Pharmaceuticals Holding AB (publ) (the “Company” or “InDex”) has, with support from the authorization granted by the annual general meeting on May 24, 2018, resolved on a directed share issue of 6,252,842 shares to a small group of investors. The subscription price is SEK 6.02 per share, corresponding to a discount in line with market conditions of 7.7 percent to the 5-day volume weighted average price and 1.3 percent to today’s closing price. InDex will receive proceeds of approximately SEK 37.5 million after transaction related costs for

InDex Pharmaceuticals Holding AB (publ) interim report January – June 2018

Updated timeline for the top line results from the CONDUCT studyPeriod April – June 2018   · Revenues amounted to SEK 0.0 (0.0) million · Operating result amounted to SEK –26.0 (–15.4) million · Result after tax amounted to SEK –26.0 (–15.2) million, corresponding to SEK –0.42 per share (–0.24) before and after dilution · Cash flow from operating activities amounted to SEK –19.7 (–18.4) million Period January – June 2018 · Revenues amounted to SEK 0.1 (0.1) million · Operating result amounted to SEK –44.8 (–37.5) million · Result after tax amounted to SEK –44.7 (–

InDex Pharmaceuticals updates timeline for top line results from the CONDUCT study to first half of 2019

August 9, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced an updated timeline for patient recruitment in the ongoing phase IIb study CONDUCT with the drug candidate cobitolimod. Top line results from the study are now expected in the first half of 2019 instead of in the fourth quarter of 2018 as previously communicated.Cobitolimod is a new type of drug under development for the treatment of moderate to severe ulcerative colitis. The CONDUCT study is a phase IIb study that will include 215 patients with left-sided moderate to severe active ulcerative colitis at approximately

Bulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)

May 24, 2018 – The Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) took place on Thursday, May 24, 2018 in the company´s premises at Tomtebodavägen 23a in Stockholm, Sweden.The complete bulletin from the Annual General Meeting (in the Swedish language) is available on the company’s website, www.indexpharma.com. For more information:Peter Zerhouni, CEOPhone: +46 8 508 847 35E-mail: peter.zerhouni@indexpharma.com PublicationThis information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse

InDex Pharmaceuticals Holding AB (publ) interim report January – March 2018

Novel formulation for oral administration of cobitolimodPeriod January – March 2018   · Revenues amounted to SEK 0.1 (0.0) million · Operating result amounted to SEK –18.8 (–22.1) million · Result after tax amounted to SEK –18.7 (–22.0) million, corresponding to SEK –0.30 per share (–0.35) before and after dilution · Cash flow from operating activities amounted to SEK –22.9 (–19.1) million · Cash and cash equivalents at the end of the period amounted to SEK 102.1 (174.1) million · Number of employees at the end of the period was 7 (7) · Number of shares at the end of

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe